-
2
-
-
78149436559
-
Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project
-
Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19): 3724-34.
-
(2010)
Blood
, vol.116
, Issue.19
, pp. 3724-3734
-
-
Sant, M.1
Allemani, C.2
Tereanu, C.3
De Angelis, R.4
Capocaccia, R.5
Visser, O.6
-
3
-
-
51649093353
-
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
-
Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do K-A, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4): 975-80.
-
(2008)
Blood
, vol.112
, Issue.4
, pp. 975-980
-
-
Tam, C.S.1
O'Brien, S.2
Wierda, W.3
Kantarjian, H.4
Wen, S.5
Do, K.-A.6
-
4
-
-
77957664665
-
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial
-
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.
-
(2010)
Lancet
, vol.376
, Issue.9747
, pp. 1164-1174
-
-
Hallek, M.1
Fischer, K.2
Fingerle-Rowson, G.3
Fink, A.M.4
Busch, R.5
Mayer, J.6
-
5
-
-
61449135843
-
Treatment of elderly patients with chronic lymphocytic leukemia
-
Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50 (2):171-8.
-
(2009)
Leuk Lymphoma
, vol.50
, Issue.2
, pp. 171-178
-
-
Eichhorst, B.1
Goede, V.2
Hallek, M.3
-
6
-
-
84879748062
-
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
-
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1): 32-42.
-
(2013)
N Engl J Med
, vol.369
, Issue.1
, pp. 32-42
-
-
Byrd, J.C.1
Furman, R.R.2
Coutre, S.E.3
Flinn, I.W.4
Burger, J.A.5
Blum, K.A.6
-
7
-
-
84896692766
-
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
-
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007.
-
(2014)
N Engl J Med
, vol.370
, Issue.11
, pp. 997-1007
-
-
Furman, R.R.1
Sharman, J.P.2
Coutre, S.E.3
Cheson, B.D.4
Pagel, J.M.5
Hillmen, P.6
-
8
-
-
84891373281
-
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial
-
O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48-58.
-
(2014)
Lancet Oncol
, vol.15
, Issue.1
, pp. 48-58
-
-
O'Brien, S.1
Furman, R.R.2
Coutre, S.E.3
Sharman, J.P.4
Burger, J.A.5
Blum, K.A.6
-
9
-
-
0037406968
-
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia
-
Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764-75.
-
(2003)
N Engl J Med
, vol.348
, Issue.18
, pp. 1764-1775
-
-
Crespo, M.1
Bosch, F.2
Villamor, N.3
Bellosillo, B.4
Colomer, D.5
Rozman, M.6
-
10
-
-
79960036578
-
Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
-
Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, et al. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-5.
-
(2011)
Nature
, vol.475
, Issue.7354
, pp. 101-105
-
-
Puente, X.S.1
Pinyol, M.2
Quesada, V.3
Conde, L.4
Ordóñez, G.R.5
Villamor, N.6
-
11
-
-
84555171449
-
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
-
Quesada V, Conde L, Villamor N, Ordóñez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44 (1):47-52.
-
(2012)
Nat Genet
, vol.44
, Issue.1
, pp. 47-52
-
-
Quesada, V.1
Conde, L.2
Villamor, N.3
Ordóñez, G.R.4
Jares, P.5
Bassaganyas, L.6
-
13
-
-
0031901577
-
Comorbidity and functional status are independent in older cancer patients
-
Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16(4):1582-7.
-
(1998)
J Clin Oncol
, vol.16
, Issue.4
, pp. 1582-1587
-
-
Extermann, M.1
Overcash, J.2
Lyman, G.H.3
Parr, J.4
Balducci, L.5
-
14
-
-
84866615945
-
Missing data in clinical studies: Issues and methods
-
Ibrahim JG, Chu H, Chen M-H. Missing data in clinical studies: issues and methods. J Clin Oncol. 2012;30(26):3297-303.
-
(2012)
J Clin Oncol
, vol.30
, Issue.26
, pp. 3297-3303
-
-
Ibrahim, J.G.1
Chu, H.2
Chen, M.-H.3
-
16
-
-
78349244388
-
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia
-
Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalda MS, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116(20):4777-87.
-
(2010)
Cancer
, vol.116
, Issue.20
, pp. 4777-4787
-
-
Shanafelt, T.D.1
Rabe, K.G.2
Kay, N.E.3
Zent, C.S.4
Jelinek, D.F.5
Reinalda, M.S.6
-
17
-
-
38549168905
-
Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia
-
Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49-56.
-
(2008)
Leuk Lymphoma
, vol.49
, Issue.1
, pp. 49-56
-
-
Thurmes, P.1
Call, T.2
Slager, S.3
Zent, C.4
Jenkins, G.5
Schwager, S.6
-
18
-
-
70350720141
-
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
-
Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009; 114(16):3382-91.
-
(2009)
Blood
, vol.114
, Issue.16
, pp. 3382-3391
-
-
Eichhorst, B.F.1
Busch, R.2
Stilgenbauer, S.3
Stauch, M.4
Bergmann, M.A.5
Ritgen, M.6
-
19
-
-
84901701451
-
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: Results of German CLL Study Group trials
-
Goede V, Cramer P, Busch R, Bergmann M, Stauch M, Hopfinger G, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German CLL Study Group trials. Haematologica. 2014;99(6):1095-100.
-
(2014)
Haematologica
, vol.99
, Issue.6
, pp. 1095-1100
-
-
Goede, V.1
Cramer, P.2
Busch, R.3
Bergmann, M.4
Stauch, M.5
Hopfinger, G.6
-
20
-
-
84894552888
-
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
-
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-10.
-
(2014)
N Engl J Med
, vol.370
, Issue.12
, pp. 1101-1110
-
-
Goede, V.1
Fischer, K.2
Busch, R.3
Engelke, A.4
Eichhorst, B.5
Wendtner, C.M.6
-
21
-
-
84892578245
-
Chronic lymphocytic leukemia in young (less than 55 years) patients: A comprehensive analysis of prognostic factors and outcomes
-
Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Schwager S, et al. Chronic lymphocytic leukemia in young (less than 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica. 2014;99(1):140-7.
-
(2014)
Haematologica
, vol.99
, Issue.1
, pp. 140-147
-
-
Parikh, S.A.1
Rabe, K.G.2
Kay, N.E.3
Call, T.G.4
Ding, W.5
Schwager, S.6
-
22
-
-
84874773634
-
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: Results of sequential Cancer and Leukemia Group B studies
-
Woyach JA, Ruppert AS, Rai K, Lin TS, Geyer S, Kolitz J, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential Cancer and Leukemia Group B studies. J Clin Oncol. 2013;31(4):440-7.
-
(2013)
J Clin Oncol
, vol.31
, Issue.4
, pp. 440-447
-
-
Woyach, J.A.1
Ruppert, A.S.2
Rai, K.3
Lin, T.S.4
Geyer, S.5
Kolitz, J.6
-
23
-
-
79953072637
-
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
-
Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117(11):3016-24.
-
(2011)
Blood
, vol.117
, Issue.11
, pp. 3016-3024
-
-
Badoux, X.C.1
Keating, M.J.2
Wang, X.3
O'Brien, S.M.4
Ferrajoli, A.5
Faderl, S.6
-
24
-
-
84866531516
-
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group
-
Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26): 3209-16.
-
(2012)
J Clin Oncol
, vol.30
, Issue.26
, pp. 3209-3216
-
-
Fischer, K.1
Cramer, P.2
Busch, R.3
Böttcher, S.4
Bahlo, J.5
Schubert, J.6
-
25
-
-
34249651313
-
CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia
-
Josefsson P, Geisler CH, Leffers H, Petersen JH, Andersen MK, Jurlander J, et al. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood. 2007;109(11): 4973-9.
-
(2007)
Blood
, vol.109
, Issue.11
, pp. 4973-4979
-
-
Josefsson, P.1
Geisler, C.H.2
Leffers, H.3
Petersen, J.H.4
Andersen, M.K.5
Jurlander, J.6
-
26
-
-
1842328565
-
11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis
-
Döhner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89(7):2516-22.
-
(1997)
Blood
, vol.89
, Issue.7
, pp. 2516-2522
-
-
Döhner, H.1
Stilgenbauer, S.2
James, M.R.3
Benner, A.4
Weilguni, T.5
Bentz, M.6
-
27
-
-
84904818973
-
Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study
-
Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014;32(12):1236-41.
-
(2014)
J Clin Oncol
, vol.32
, Issue.12
, pp. 1236-1241
-
-
Hillmen, P.1
Gribben, J.G.2
Follows, G.A.3
Milligan, D.4
Sayala, H.A.5
Moreton, P.6
-
28
-
-
84904431445
-
A phase 2 study of the selective phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor idelalisib (GS-1101) in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
-
abstr.7005
-
O'Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of the selective phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor idelalisib (GS-1101) in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol. 2013;31(suppl.): abstr.7005.
-
(2013)
J Clin Oncol
, vol.31
-
-
O'Brien, S.M.1
Lamanna, N.2
Kipps, T.J.3
-
29
-
-
84896480883
-
Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): Results of the phase III study complement 1 (OMB110911)
-
Hillmen P, Robak T, Janssens A, Govindbabu K, Grosicki S, Mayer J, et al. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). Blood (ASH Annual Meeting Abstracts). 2013; 122:528.
-
(2013)
Blood (ASH Annual Meeting Abstracts)
, vol.122
, pp. 528
-
-
Hillmen, P.1
Robak, T.2
Janssens, A.3
Govindbabu, K.4
Grosicki, S.5
Mayer, J.6
-
30
-
-
84899638389
-
Prognostic and predictive factors in patients with chronic lymphocytic leukemia: Relevant in the era of novel treatment approaches?
-
Mertens D, Stilgenbauer S. Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches? J Clin Oncol. 2014;32(9):869-72.
-
(2014)
J Clin Oncol
, vol.32
, Issue.9
, pp. 869-872
-
-
Mertens, D.1
Stilgenbauer, S.2
|